Hoffmann-la Roche Inc.

C4 Therapeutics, Inc.

F. Hoffmann-la Roche Ag

David Hewings

Cosimo Dolente

Bernd Kuhn

Georg Jaeschke

Antonio Ricci

Daniel Rueher

Annick Goergler

Yvonne Alice Nagel

Christa Ulrike Obst-sander

Juergen Wichmann

Christopher G Nasveschuk

Daniel Hunziker

Ulrike Obst Sander

Sandra Steiner

Yanke Liang

Martin Duplessis

Daniela Krummenacher

Katrina L Jackson

Mark E Fitzgerald

Piergiorgio Francesco Tommaso Pettazzoni

Christa Ulrike Obst-Sander

Roger David Norcross

The present invention provides compounds or their pharmaceutically acceptable salts and their pharmaceutical compositions that can be administered to a host such as a human in need thereof for the treatment of a disorder, such as cancer, mediated by mutant BRAF. The compounds efficiently degrade Class I, II and III mutant BRAF proteins.

Therapeutics for the degradation of mutant BRAF

The application relates to (106) specific heterocyclic compounds comprising a thiazole ring, an indazol and a 6,7-dihydro-5H-pyrrolo[1,2-c]imidazole system, to pharmaceutical compositions containing them and their medical use. The compounds are described as selective allosteric inhibitors of T790M/L858R, T790M/L858R/C797S, L858R, L858R/C797S containing EGFR mutants and thus useful for the treatment of cancer, in particular non-small cell lung cancer.

EGFR inhibitors for the treatment of cancer

The application relates to a compound of formula (I) containing a thiazole ring, an indazol ring and a 6,7-dihydro-5H-pyrrolo[1,2-c]imidazole ring system, to pharmaceutical compositions containing it and its medical use. The compounds are described as selective allosteric inhibitors of T790M/L858R, T790M/L858R/C797S, L858R, L858R/C797S containing EGFR mutants and thus useful for the treatment of cancer, in particular non-small cell lung cancer.

EGFR inhibitor for the treatment of cancer

Growing community of inventors

Basel, Switzerland

David Hewings